MedTrace Logo

Clinical Study of (A-319) in the Treatment of Active Rheumatoid Arthritis

NCT07347860 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-01-16

No results posted yet for this study

Summary

The primary objective of the study was to evaluate the safety and tolerability of A-319 in patients with active rheumatoid arthritis.

Conditions

  • Rheumatoid Arthritis (RA)

Interventions

BIOLOGICAL

A-319

A-319 will be dosed according to the assigned group.

Sponsors & Collaborators

  • ITabMed Co., Ltd.

    collaborator INDUSTRY

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-08
Primary Completion
2027-08-31
Completion
2027-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07347860 on ClinicalTrials.gov